Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 7 Carcinoma, Non-Small-Cell Lung 4 Triple Negative Breast Neoplasms 3 Hodgkin Disease 3 Rhabdomyosarcoma, Embryonal 2 Rhabdomyosarcoma, Alveolar 2 Rhabdomyosarcoma 2 Neoplasm Metastasis 2 Uterine Cervical Neoplasms 1 Sarcoma 1 Recurrence 1 Neoplasms 1 Lung Neoplasms 1 Lung Diseases, Interstitial 1 HR+HER2- Breast Cancer 1 Desmoplastic Small Round Cell Tumor 1 Adenocarcinoma 1

Interventions

pembrolizumab 36 Bevacizumab 25 Cyclophosphamide 22 Blood Specimen Collection 18 Nivolumab 17 Carboplatin 15 Standard of Care 14 Paclitaxel 14 atezolizumab 13 Gemcitabine 13 Exercise 13 Pemetrexed 11 Fluorouracil 11 Doxorubicin 11 Cisplatin 11 Cetuximab 10 Radiotherapy 9 Oxaliplatin 9 Magnetic Resonance Spectroscopy 9 Leucovorin 9 Docetaxel 9 durvalumab 8 abemaciclib 8 Temozolomide 8 Surveys and Questionnaires 8 Rituximab 8 Prednisone 8 Biopsy 8 130-nm albumin-bound paclitaxel 8 olaparib 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × Vinorelbine × 90 days × Clear all

NCT05999994 2026-03-27

CAMPFIRE

Eli Lilly and Company

Phase 2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡